CA Patent

CA2856043C — Nasal formulation

Assigned to Teva Branded Pharmaceutical Products R&D Inc · Expires 2017-01-17 · 9y expired

What this patent protects

This invention relates to a solution formulation for nasal administration comprising azelastine, beclomethasone dipropionate, a co-solvent, an acid and an HFA propellant.

USPTO Abstract

This invention relates to a solution formulation for nasal administration comprising azelastine, beclomethasone dipropionate, a co-solvent, an acid and an HFA propellant.

Drugs covered by this patent

beclomethasone-dipropionate (BECLOMETHASONE DIPROPIONATE)

Patent Metadata

Patent number: CA2856043C
Jurisdiction: CA
Classification: —
Expires: 2017-01-17
Drug substance claim: No
Drug product claim: No
Assignee: Teva Branded Pharmaceutical Products R&D Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.